OVERVIEW OF ACTIVITY

More than 45 drug products are currently labeled for use in the management of hematologic malignancies, comprising more than 55 distinct FDA-approved indications. This extensive list of available treatment options poses a challenge to clinicians who must maintain current knowledge of appropriate clinical management strategies. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading oncology investigators. By providing information on the latest research developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies to facilitate optimal patient care.

LEARNING OBJECTIVES

• Utilize prognostic and predictive clinical and molecular markers to aid in treatment decision-making for patients with hematologic malignancies.
• Recall the emerging data for novel agents and combinations in the treatment of indolent and aggressive non-Hodgkin lymphoma (NHL).
• Appraise the role of maintenance rituximab in the management of follicular lymphoma.
• Counsel patients with chronic myelogenous leukemia (CML) about the long-term outcomes associated with the use of tyrosine kinase inhibitors for PDGFR- and c-kit-mediated cellular events.
• Formulate therapeutic interventions for patients with imatinib-resistant CML, and delineate strategies for monitoring disease progression.
• Recommend primary therapy for patients with chronic lymphocytic leukemia (CLL), considering emerging clinical research on the use of novel chemotherapeutics, monoclonal antibodies and immunomodulatory agents.
• Develop an algorithm for the diagnosis, genomic classification and risk-stratified treatment of myelodysplastic syndrome (MDS).
• Devise individualized treatment plans for patients with multiple myeloma (MM), considering baseline eligibility for stem cell transplant and emerging clinical trial data with active novel agents.
• Counsel appropriately selected patients about participation in ongoing clinical research studies.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should review the CME information, listen to the CDs and complete the Post-test and Educational Assessment and Credit Form located on our website at ResearchToPractice.com/HOU. ResearchToPractice.com/HOU includes an easy-to-use, interactive version of this monograph with links to relevant full-text articles, abstracts, trial information and other web resources indicated here in blue underlined text.

This program is supported by educational grants from Bayer Pharmaceuticals Corporation, Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium Pharmaceuticals Inc and Ortho Biotech Products LP.

Table of Contents

Top of Page

Home

EDITOR
Neil Love, MD

INTERVIEWS
Bruce D Cheson, MD
- Select publications

Hagop M Kantarjian, MD
- Select publications

Sagar Lonial, MD
- Select publications

Hematologic Oncology Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office